Torrent Pharmaceuticals has posted a robust 30 percent jump in its consolidated profit after tax (PAT) at Rs 591 crore for the September quarter, driven by strong sales across key markets. The Ahmedabad-based drugmaker had posted a PAT of Rs 453 crore in the same quarter last year.

According to a regulatory filing, the company’s revenue for the second quarter rose to Rs 3,302 crore, compared to Rs 2,889 crore in the year-ago period.

India revenues stood at Rs 1,820 crores were up by 12% led by outperformance in focus therapies.

In India, Torrent Pharma’s largest market, revenues grew 12% to Rs 1,820 crore, driven by strong performance in its focus therapy areas. The company’s international operations also delivered healthy growth — revenues from Brazil rose 21% to Rs 318 crore, while th

See Full Page